SEC Comment Letter 0000000000-24-010780 to Dermata Therapeutics, Inc. (DRMA)
Dermata Therapeutics, Inc.
Date: Sept. 23, 2024 · CIK: 0001853816 · Accession: 0000000000-24-010780
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282223
Letter
September 23, 2024 Kyri Van Hoose Chief Financial Officer Dermata Therapeutics, Inc. 3525 Del Mar Heights Rd., #322 San Diego, CA 92130 Re:Dermata Therapeutics, Inc. Registration Statement on Form S-3 Filed September 19, 2024 File No. 333-282223 Dear Kyri Van Hoose: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Tracy F. Buffer
Show Raw Text
September 23, 2024
Kyri Van Hoose
Chief Financial Officer
Dermata Therapeutics, Inc.
3525 Del Mar Heights Rd., #322
San Diego, CA 92130
Re:Dermata Therapeutics, Inc.
Registration Statement on Form S-3
Filed September 19, 2024
File No. 333-282223
Dear Kyri Van Hoose:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Tracy F. Buffer